EC Approves Tepkinly as First Bispecific-Based Therapy for Follicular Lymphomahttps://www.biopharminternational.com/view/european-commission-approves-tepkinly-plus-r2-as-first-bispecific-based-therapy-for-relapsed-or-refractory-follicular-lymphoma by consumer451 • 14 days ago 1 1 14 days agoBIbiopharminternational.com